Introduction
Multifocal or diffuse triphasic waves are electro-encephalographic (EEG) patterns seen in toxic-metabolic encephalopathies in adults. Previously thought to be specific to hepatic encephalopathy, 1 they have been described in a variety of other etiologies such as hyper-azotemia, hypoxia, thyroid disease, hyperammonemia caused by valproic acid, cefepime intoxication in patients with chronic renal failure and various other drug-related conditions including lithium, naproxen, levodopa, as well as in a variety of non-metabolic causes. [2] [3] [4] [5] [6] Levetiracetam is a new anti-epileptic drug with renal elimination and no hepatic metabolism which is widely homologated for partial onset or primary generalized seizures, as well as epileptic and non-epileptic myoclonic conditions. 6, 7 Reversible dosedependent side effects include sedation and dizziness. We report the first case of metabolic encephalopathy with triphasic waves associated with levetiracetam intoxication in a patient with cortical myoclonus of vascular origin.
Case report
In March 2007, an 80-year-old woman was admitted to our hospital for repetitive generalized myoclonic jerks, also involving the diaphragma, together with a moderate confusional state.
Another similar episode had already occurred in 2001, culminating in a secondary generalized tonic-clonic seizure. She had been discharged on valproic acid with the diagnosis of post-stroke symptomatic seizures. The treatment of valproic acid was stopped a year later, in 2002, because of drug-induced hyperammonemic encephalopathy and was replaced with levetiracetam (2Â 1000 mg/day). Her medical history included hypertension, noninsulin-dependant diabetes mellitus and chronic renal failure, together with a discrete vascular parkinsonism in the context of a widespread vascular leuco-encephalopathy. The rest of the treatment consisted in verapamil, propranolol, metformine, oxazepam, escitalopram and levodopa/benserazide (3Â 100/ 25 mg/day) with no recent treatment change. Neurological examination showed resting and action myoclonus of the four extremities together with vocalization induced by synchronous diaphragmatic myoclonus. There was a moderate confusional state but no other relevant neurological feature on examination. The myoclonus stopped spontaneously a few days after admission. Blood tests showed a normal count of blood cells, normal electrolytes (natrium, kalium, calcium, magnesium), increased creatinin level (148 mmol/l norm 35-88, clearance: 29 ml/min, norm corrected for age: 40-75 ml/min), normal liver enzymes, normal serum ammonium, normal thyroid function and absent anti-thyroid antibodies. A lumbar puncture showed no abnormality in the cerebro-spinal fluid. The MRI showed a severe vascular leuco-encephalopathy together with a right prefrontal cortical vascular lesion. The EEG after the cessation of the myoclonus showed a background slowing with no epileptiform activity. Neuropsychological examination revealed executive and memory Triphasic waves are seen in the electro-encephalogram of adult patients with toxic-metabolic encephalopathies of various origins. Levetiracetam is a broad spectrum anti-epileptic drug with renal elimination and no hepatic metabolism. We describe the case of encephalopathy with triphasic waves concomitant with levetiracetam accumulation in a patient with chronic renal failure. The condition was reversible after down-titration of levetiracetam with no change of the renal function. Other causes of metabolic encephalopathy were excluded. Moreover, this patient suffered from a probable cortical myoclonus that relapsed after cessation of the drug but was well controlled by a low dosage adapted to the renal failure. In cases of metabolic encephalopathy with triphasic waves in a patient with renal failure taking levetiracetam, it is important to exclude toxic accumulation of levetiracetam among other causes.
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disorder compatible with the vascular lesions. The patient was discharged with no treatment change. Two months later, she was readmitted for a relapse of very frequent myoclonic jerks occuring in a status myoclonicus presentation, again combined with a moderate confusional state. EEG showed a diffuse theta-delta slowing with prominent multifocal triphasic waves (Fig. 1a) . Generalized myoclonic jerks involving the diaphragma occurred during the recording with no paroxysmal EEG correlate.
Standard laboratory tests showed a stable renal insufficiency. Since the patient was taking 2Â 1000 mg/day of levetiracetam in the context of renal failure, accumulation and intoxication was suspected and the drug lowered to 2Â 250 mg/day. Three days later, the myoclonic jerks had disappeared, the cognitive functions were back to baseline and the EEG showed normal background activity (Fig. 1b) Two days later, there was a renewed intense relapse of myoclonic jerks with no worsening of the renal function, infection or electrolyte imbalance. During repetition of the EEG, multiple jerks were recorded. An epileptic focus with spikes and polyspikes located over the frontal midline was observed, suggesting cortical origin of the myocloni (Fig. 1c and d) . Levetiracetam was reintroduced at the dose of 2Â 250 mg/day. For a more rapid relief of the patient, small doses of clonazepam (2Â 0.25 mg/day) were added for 3 days, then halved for 1 day and finally stopped.
The myoclonus did not relapse after cessation of clonazepam and the last plasma level of levetiracetam at discharge was within therapeutic range (90 mmol/l). Somatosensory evoked potentials, performed during low-dose levetiracetam therapy in the absence of myoclonus, did not reveal giant potentials. Follow-up 6 months after hospital discharge revealed a stable condition with no relapse of myoclonus.
Discussion
To the best of our knowledge, this is the first report of metabolic encephalopathy with triphasic waves so closely associated with intoxication with levetiracetam in the context of chronic renal failure.
The improvement in the clinical condition and the EEG after reduction of this drug as well as concomitant normalization of the elevated drug plasma level are strong arguments supporting this etiology. The stability of the renal function despite dramatic clinical and EEG changes does not suggest a direct participation of this condition in the clinical picture, except by causing the accumulation of the involved drug. No other treatment change could explain this rapid evolution highly suggestive of a toxicmetabolic origin. The patient was also taking levodopa reported to cause metabolic encephalopathy in the context of dose increase and for higher baseline doses. 10 Since this drug has a hepatic metabolism and was only given in small dosage in a patient with no hepatic dysfunction, its role in the encephalopathy is unlikely. Moreover, no other signs of levodopa overdose, such as choreoathetotic dyskinesia, were observed. Although they can be toxic to the CNS, the other concomitant drugs have not been reported to be related to encephalopathy with triphasic waves. Among other possible metabolic causes, there was no clinical sign or biological sign of thyroid disease. Interestingly, levetiracetam has been shown to undergo a significant in vivo metabolism when serum was not quickly separated from the whole blood 11 and this has to be considered when assessing the level of this drug, especially if this is done retrospectively. In our hospital, serum was separated from whole blood following the usual practice of the local chemistry laboratory within a few hours. According to the study by Patsalos et al., in situ metabolism of levetiracetam can only affect measured levels of the drug if whole blood is conserved and the serum not stored separately. Therefore, in our laboratory setting, in situ metabolism of levetiracetam would not have exceeded a few percent of the total blood level in the worst scenario and could not explain the 3-fold difference of serum drug levels obtained in consecutive measurements.
Levetiracetam has reported anti-myoclonic effect acting on cortical, and subcortical as well as spinal myoclonus. 6, [12] [13] [14] The spikes recorded on the EEG after complete cessation of levetiracetam strongly suggest a cortical origin of the myoclonus, probably secondary to a vascular lesion in the context of a diffuse vascular encephalopathy. The absence of giant evoked potentials, tested under levetiracetam treatment, does not exclude the cortical origin suggested by the EEG, since giant evoked potentials reportedly become normal after institution of anti-myoclonic treatment and can even be absent in untreated patients with cortical myoclonus. 14 In this particular case, levetiracetam seems to have a bell-shaped effect on the generalized myoclonus: at therapeutic doses adapted to the renal function, the drug suppressed the jerks, while, at supra-therapeutic dosage, it induced a toxic encephalopathy that lowered the threshold for the myoclonus and caused it to recur. This case adds evidence to the potent anti-myoclonic effect of levetiracetam at therapeutic doses. Triphasic waves on the EEG in a patient with renal failure taking levetiracetam should not only suggest the possibility of renal/uremic encephalopathy but also raise the concern of possible toxic accumulation of levetiracetam as a significant contributor to the toxic-metabolic encephalopathy. In clinical practice, a single definite trigger of the encephalopathy is often hard to isolate in elderly patients with multiple comorbidities and multiple drug treatments. Therefore, even if levetiracetam might have acted as a concomitant factor rather than as the single trigger, the consequences for the clinical management remain the same and aim at reducing concomitant aggravating/ triggering metabolic and toxic factors. This is of clinical relevance since an increasing number of elderly patients with multiple comorbidities are treated with levetiracetam and these patients are precisely those at risk for toxic/metabolic encephalopathy because of their medical condition and multiple drug treatments.
